Multiple myeloma (MM) outcomes have continually improved over the past 2 decades.1 Overall survival (OS) is improved with lenalidomide maintenance therapy after hematopoietic stem cell transplantation (HSCT).2 Patients with high-risk MM generally experience more aggressive disease behavior and poorer outcomes than those with standard-risk MM, and the addition of a proteasome inhibitor (PI) in the maintenance phase is usually suggested for these patients to overcome these worse outcomes.
